



Drug Discovery for Infectious Diseases—Second Edition

Guest Editors:

Dr. Ákos Jerzsele

1. Department of Pharmacology and Toxicology, University of Veterinary Medicine, István utca 2, H-1078 Budapest, Hungary
2. National Laboratory of Infectious Animal Diseases, Antimicrobial Resistance, Veterinary Public Health and Food Chain Safety, University of Veterinary Medicine, István utca 2, H-1078 Budapest, Hungary

Dr. Dóra Kovács

Department of Pharmacology and Toxicology, University of Veterinary Medicine Budapest, Budapest, Hungary

Deadline for manuscript submissions:

31 October 2024

Message from the Guest Editors

Dear Colleagues,

Infectious diseases encompass a wide range of diseases caused by viruses, bacteria, fungi and parasites, all of which have serious consequences for human health. The rapid emergence of new viral and parasitic diseases, as well as the spread of antimicrobial resistance, is also putting drug research at a disadvantage, posing a challenge to the biomedical research field to develop new drugs and drug innovation strategies to keep pace with these new needs. Recent pandemics in particular highlight the need for novel antiviral drugs in several areas of human and animal health.

This Special Issue welcomes reviews and papers describing host-entry and reproduction of the pathogen and pathomechanism of diseases at the molecular level, as well as those reporting on the discovery of new drug candidates that affect these processes. Innovative drug discovery strategies, including repositioning strategies from other pharmacological areas, drug combinations or multiple-targeting ligands, as well as new drug formulations for improved ADME, also represent suitable subjects of submitted papers.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research

Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA

2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

High Visibility: indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

Journal Rank: JCR - Q1 (*Pharmacology & Pharmacy*) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
[X@Biomed_MDPI](#)